“Durable Maintenance of EASI-90 With Amlitelimab in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Results from the STREAM-AD Phase 2b Trial”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s606. https://doi.org/10.25251/yhn4cs07.